Inovio Pharmaceuticals, Inc.
INONASDAQHealthcare● Active
$1.09
+$0.02(+1.87%)
Market Cap$58412952
P/E Ratio—
52W High$2.98
52W Low$1.03
Inovio Pharmaceuticals, Inc. (INO) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · INO · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.07M | $0.22M | $0.83M | $10.26M | $1.77M |
| Cost of Revenue | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $0.07M | $0.22M | $0.83M | $10.26M | $1.77M |
| Gross Margin %(computed) | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $54.21M | $75.62M | $86.68M | $187.65M | $249.24M |
| G&A Expenses | $32.68M | $37.00M | $47.58M | $90.19M | $53.75M |
| Total Operating Expenses | $86.89M | $112.62M | $144.77M | $277.84M | $302.99M |
| Operating Income | ($86.82M) | ($112.40M) | ($143.94M) | ($267.57M) | ($301.22M) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $2.42M | $4.77M | $8.13M | $4.78M | $3.36M |
| Interest Expense | $0.00M | $0.18M | $1.22M | $1.25M | $1.94M |
| Income Before Tax | ($84.95M) | ($107.25M) | ($135.12M) | ($279.82M) | ($303.66M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($84.95M) | ($107.25M) | ($135.12M) | ($279.82M) | ($303.66M) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.81 | $-3.95 | $-6.09 | $-14.07 | $-1.42 |
| Wtd Avg Shares | 468.86M | 27.16M | 22.17M | 19.89M | 214.62M |
| EBITDA | ($81.96M) | ($103.95M) | ($130.39M) | ($270.90M) | ($296.56M) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Inovio Pharmaceuticals, Inc. data
About Inovio Pharmaceuticals, Inc. (INO) Income Statement
Inovio Pharmaceuticals, Inc. (INO) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, INO reported revenue of $0.00B, gross profit of $0.00B (gross margin 100.00%), and net income of ($0.08B) — a net profit margin of -130000.00%.
Frequently asked questions
INO · 4 questionsInovio Pharmaceuticals, Inc. (INO) reported revenue of $0.00B for 2025, down 70.0% year-over-year.
INO revenueINO salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09